Strs Ohio Buys Shares of 16,600 Vaxcyte, Inc. $PCVX

Key Points

• Strs Ohio has acquired a new position in Vaxcyte, Inc., purchasing 16,600 shares valued at approximately $627,000 in the first quarter.
• Vaxcyte's stock has recently seen a 2.6% decrease, with a current market cap of $4.12 billion and a price-to-earnings ratio of -7.73.
• Analysts have a consensus rating of "Buy" for Vaxcyte, with an average price target of $106.25, indicating potential growth despite recent earnings misses.

Strs Ohio acquired a new position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 16,600 shares of the company's stock, valued at approximately $627,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its stake in Vaxcyte by 10.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock worth $112,000 after purchasing an additional 293 shares in the last quarter. Avior Wealth Management LLC lifted its position in Vaxcyte by 5.3% in the first quarter. Avior Wealth Management LLC now owns 6,799 shares of the company's stock valued at $257,000 after purchasing an additional 343 shares during the period. US Bancorp DE lifted its stake in shares of Vaxcyte by 7.2% during the 1st quarter. US Bancorp DE now owns 5,344 shares of the company's stock worth $202,000 after purchasing an additional 357 shares during the period. Xponance Inc. raised its stake in Vaxcyte by 4.7% during the first quarter. Xponance Inc. now owns 9,320 shares of the company's stock valued at $352,000 after buying an additional 415 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Vaxcyte by 1.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,635 shares of the company's stock valued at $1,119,000 after buying an additional 436 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Stock Down 2.6%

Shares of PCVX opened at $31.75 on Friday. The stock has a market cap of $4.12 billion, a price-to-earnings ratio of -7.73 and a beta of 1.04. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $118.62. The business has a 50-day simple moving average of $32.84 and a two-hundred day simple moving average of $37.58.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same quarter in the prior year, the business posted ($1.10) EPS. On average, equities analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PCVX. The Goldman Sachs Group initiated coverage on Vaxcyte in a research report on Friday, September 12th. They set a "neutral" rating and a $38.00 target price for the company. Cowen reissued a "buy" rating on shares of Vaxcyte in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Vaxcyte has an average rating of "Buy" and a consensus price target of $106.25.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.